2018-2023 Global Primary Aldosteronism Market Report (Status and Outlook)
The report requires updating with new data and is sent in 48 hours after order is placed.
In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Primary Aldosteronism market for 2018-2023.
Primary aldosteronism refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels. This abnormality is caused by hyperplasia or tumors. Many suffer from fatigue, potassium deficiency and high blood pressure which may cause poor vision, confusion or headaches.
The treatment for hyperaldosteronism depends on the underlying cause. In people with a single benign tumor (adenoma), surgical removal (adrenalectomy) may be curative. This is usually performed laparoscopically, through several very small incisions. For people with hyperplasia of both glands, successful treatment is often achieved with spironolactone or eplerenone, drugs that block the effect of aldosterone.
Over the next five years, LPI(LP Information) projects that Primary Aldosteronism will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
This report presents a comprehensive overview, market shares and growth opportunities of Primary Aldosteronism market by product type, application, key companies and key regions.
To calculate the market size, LP Information considers value generated from the sales of the following segments:
Segmentation by product type:
Research objectives
In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Primary Aldosteronism market for 2018-2023.
Primary aldosteronism refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels. This abnormality is caused by hyperplasia or tumors. Many suffer from fatigue, potassium deficiency and high blood pressure which may cause poor vision, confusion or headaches.
The treatment for hyperaldosteronism depends on the underlying cause. In people with a single benign tumor (adenoma), surgical removal (adrenalectomy) may be curative. This is usually performed laparoscopically, through several very small incisions. For people with hyperplasia of both glands, successful treatment is often achieved with spironolactone or eplerenone, drugs that block the effect of aldosterone.
Over the next five years, LPI(LP Information) projects that Primary Aldosteronism will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
This report presents a comprehensive overview, market shares and growth opportunities of Primary Aldosteronism market by product type, application, key companies and key regions.
To calculate the market size, LP Information considers value generated from the sales of the following segments:
Segmentation by product type:
- Type I
- Type II
- Hospitals & Clinics
- Research Organization
- Academic Institutes
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Spain
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Sun Pharmaceutical Industries
- Bristol Laboratories
- CMP Pharma
- Koninklijke Philips
- GE Healthcare
- Siemens
- Shimadzu Corporation
- Canon
Research objectives
- To study and analyze the global Primary Aldosteronism market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
- To understand the structure of Primary Aldosteronism market by identifying its various subsegments.
- Focuses on the key global Primary Aldosteronism players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
- To analyze the Primary Aldosteronism with respect to individual growth trends, future prospects, and their contribution to the total market.
- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
- To project the size of Primary Aldosteronism submarkets, with respect to key regions (along with their respective key countries).
- To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
- To strategically profile the key players and comprehensively analyze their growth strategies.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Primary Aldosteronism Market Size 2013-2023
2.1.2 Primary Aldosteronism Market Size CAGR by Region
2.2 Primary Aldosteronism Segment by Type
2.2.1 Type I
2.2.2 Type II
2.3 Primary Aldosteronism Market Size by Type
2.3.1 Global Primary Aldosteronism Market Size Market Share by Type (2013-2018)
2.3.2 Global Primary Aldosteronism Market Size Growth Rate by Type (2013-2018)
2.4 Primary Aldosteronism Segment by Application
2.4.1 Hospitals & Clinics
2.4.2 Research Organization
2.4.3 Academic Institutes
2.5 Primary Aldosteronism Market Size by Application
2.5.1 Global Primary Aldosteronism Market Size Market Share by Application (2013-2018)
2.5.2 Global Primary Aldosteronism Market Size Growth Rate by Application (2013-2018)
3 GLOBAL PRIMARY ALDOSTERONISM BY PLAYERS
3.1 Global Primary Aldosteronism Market Size Market Share by Players
3.1.1 Global Primary Aldosteronism Market Size by Players (2016-2018)
3.1.2 Global Primary Aldosteronism Market Size Market Share by Players (2016-2018)
3.2 Global Primary Aldosteronism Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PRIMARY ALDOSTERONISM BY REGIONS
4.1 Primary Aldosteronism Market Size by Regions
4.2 Americas Primary Aldosteronism Market Size Growth
4.3 APAC Primary Aldosteronism Market Size Growth
4.4 Europe Primary Aldosteronism Market Size Growth
4.5 Middle East & Africa Primary Aldosteronism Market Size Growth
5 AMERICAS
5.1 Americas Primary Aldosteronism Market Size by Countries
5.2 Americas Primary Aldosteronism Market Size by Type
5.3 Americas Primary Aldosteronism Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Primary Aldosteronism Market Size by Countries
6.2 APAC Primary Aldosteronism Market Size by Type
6.3 APAC Primary Aldosteronism Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 EUROPE
7.1 Europe Primary Aldosteronism by Countries
7.2 Europe Primary Aldosteronism Market Size by Type
7.3 Europe Primary Aldosteronism Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Primary Aldosteronism by Countries
8.2 Middle East & Africa Primary Aldosteronism Market Size by Type
8.3 Middle East & Africa Primary Aldosteronism Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 GLOBAL PRIMARY ALDOSTERONISM MARKET FORECAST
10.1 Global Primary Aldosteronism Market Size Forecast (2018-2023)
10.2 Global Primary Aldosteronism Forecast by Regions
10.2.1 Global Primary Aldosteronism Forecast by Regions (2018-2023)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Primary Aldosteronism Forecast by Type
10.8 Global Primary Aldosteronism Forecast by Application
11 KEY PLAYERS ANALYSIS
11.1 Pfizer
11.1.1 Company Details
11.1.2 Primary Aldosteronism Product Offered
11.1.3 Pfizer Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.1.4 Main Business Overview
11.1.5 Pfizer News
11.2 Sun Pharmaceutical Industries
11.2.1 Company Details
11.2.2 Primary Aldosteronism Product Offered
11.2.3 Sun Pharmaceutical Industries Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.2.4 Main Business Overview
11.2.5 Sun Pharmaceutical Industries News
11.3 Bristol Laboratories
11.3.1 Company Details
11.3.2 Primary Aldosteronism Product Offered
11.3.3 Bristol Laboratories Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.3.4 Main Business Overview
11.3.5 Bristol Laboratories News
11.4 CMP Pharma
11.4.1 Company Details
11.4.2 Primary Aldosteronism Product Offered
11.4.3 CMP Pharma Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.4.4 Main Business Overview
11.4.5 CMP Pharma News
11.5 Koninklijke Philips
11.5.1 Company Details
11.5.2 Primary Aldosteronism Product Offered
11.5.3 Koninklijke Philips Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.5.4 Main Business Overview
11.5.5 Koninklijke Philips News
11.6 GE Healthcare
11.6.1 Company Details
11.6.2 Primary Aldosteronism Product Offered
11.6.3 GE Healthcare Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.6.4 Main Business Overview
11.6.5 GE Healthcare News
11.7 Siemens
11.7.1 Company Details
11.7.2 Primary Aldosteronism Product Offered
11.7.3 Siemens Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.7.4 Main Business Overview
11.7.5 Siemens News
11.8 Shimadzu Corporation
11.8.1 Company Details
11.8.2 Primary Aldosteronism Product Offered
11.8.3 Shimadzu Corporation Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.8.4 Main Business Overview
11.8.5 Shimadzu Corporation News
11.9 Canon
11.9.1 Company Details
11.9.2 Primary Aldosteronism Product Offered
11.9.3 Canon Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.9.4 Main Business Overview
11.9.5 Canon News
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Primary Aldosteronism Market Size 2013-2023
2.1.2 Primary Aldosteronism Market Size CAGR by Region
2.2 Primary Aldosteronism Segment by Type
2.2.1 Type I
2.2.2 Type II
2.3 Primary Aldosteronism Market Size by Type
2.3.1 Global Primary Aldosteronism Market Size Market Share by Type (2013-2018)
2.3.2 Global Primary Aldosteronism Market Size Growth Rate by Type (2013-2018)
2.4 Primary Aldosteronism Segment by Application
2.4.1 Hospitals & Clinics
2.4.2 Research Organization
2.4.3 Academic Institutes
2.5 Primary Aldosteronism Market Size by Application
2.5.1 Global Primary Aldosteronism Market Size Market Share by Application (2013-2018)
2.5.2 Global Primary Aldosteronism Market Size Growth Rate by Application (2013-2018)
3 GLOBAL PRIMARY ALDOSTERONISM BY PLAYERS
3.1 Global Primary Aldosteronism Market Size Market Share by Players
3.1.1 Global Primary Aldosteronism Market Size by Players (2016-2018)
3.1.2 Global Primary Aldosteronism Market Size Market Share by Players (2016-2018)
3.2 Global Primary Aldosteronism Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PRIMARY ALDOSTERONISM BY REGIONS
4.1 Primary Aldosteronism Market Size by Regions
4.2 Americas Primary Aldosteronism Market Size Growth
4.3 APAC Primary Aldosteronism Market Size Growth
4.4 Europe Primary Aldosteronism Market Size Growth
4.5 Middle East & Africa Primary Aldosteronism Market Size Growth
5 AMERICAS
5.1 Americas Primary Aldosteronism Market Size by Countries
5.2 Americas Primary Aldosteronism Market Size by Type
5.3 Americas Primary Aldosteronism Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Primary Aldosteronism Market Size by Countries
6.2 APAC Primary Aldosteronism Market Size by Type
6.3 APAC Primary Aldosteronism Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 EUROPE
7.1 Europe Primary Aldosteronism by Countries
7.2 Europe Primary Aldosteronism Market Size by Type
7.3 Europe Primary Aldosteronism Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Primary Aldosteronism by Countries
8.2 Middle East & Africa Primary Aldosteronism Market Size by Type
8.3 Middle East & Africa Primary Aldosteronism Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 GLOBAL PRIMARY ALDOSTERONISM MARKET FORECAST
10.1 Global Primary Aldosteronism Market Size Forecast (2018-2023)
10.2 Global Primary Aldosteronism Forecast by Regions
10.2.1 Global Primary Aldosteronism Forecast by Regions (2018-2023)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Primary Aldosteronism Forecast by Type
10.8 Global Primary Aldosteronism Forecast by Application
11 KEY PLAYERS ANALYSIS
11.1 Pfizer
11.1.1 Company Details
11.1.2 Primary Aldosteronism Product Offered
11.1.3 Pfizer Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.1.4 Main Business Overview
11.1.5 Pfizer News
11.2 Sun Pharmaceutical Industries
11.2.1 Company Details
11.2.2 Primary Aldosteronism Product Offered
11.2.3 Sun Pharmaceutical Industries Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.2.4 Main Business Overview
11.2.5 Sun Pharmaceutical Industries News
11.3 Bristol Laboratories
11.3.1 Company Details
11.3.2 Primary Aldosteronism Product Offered
11.3.3 Bristol Laboratories Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.3.4 Main Business Overview
11.3.5 Bristol Laboratories News
11.4 CMP Pharma
11.4.1 Company Details
11.4.2 Primary Aldosteronism Product Offered
11.4.3 CMP Pharma Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.4.4 Main Business Overview
11.4.5 CMP Pharma News
11.5 Koninklijke Philips
11.5.1 Company Details
11.5.2 Primary Aldosteronism Product Offered
11.5.3 Koninklijke Philips Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.5.4 Main Business Overview
11.5.5 Koninklijke Philips News
11.6 GE Healthcare
11.6.1 Company Details
11.6.2 Primary Aldosteronism Product Offered
11.6.3 GE Healthcare Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.6.4 Main Business Overview
11.6.5 GE Healthcare News
11.7 Siemens
11.7.1 Company Details
11.7.2 Primary Aldosteronism Product Offered
11.7.3 Siemens Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.7.4 Main Business Overview
11.7.5 Siemens News
11.8 Shimadzu Corporation
11.8.1 Company Details
11.8.2 Primary Aldosteronism Product Offered
11.8.3 Shimadzu Corporation Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.8.4 Main Business Overview
11.8.5 Shimadzu Corporation News
11.9 Canon
11.9.1 Company Details
11.9.2 Primary Aldosteronism Product Offered
11.9.3 Canon Primary Aldosteronism Revenue, Gross Margin and Market Share (2016-2018)
11.9.4 Main Business Overview
11.9.5 Canon News
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES AND FIGURES
Table Product Specifications of Primary Aldosteronism
Figure Primary Aldosteronism Report Years Considered
Figure Market Research Methodology
Figure Global Primary Aldosteronism Market Size Growt
Table Product Specifications of Primary Aldosteronism
Figure Primary Aldosteronism Report Years Considered
Figure Market Research Methodology
Figure Global Primary Aldosteronism Market Size Growt
